Regeneron (REGN) Moves Higher on Strong EYLEA FY12 Sales Outlook, Q4 Numbers
REGN Hot Sheet
Financial Fact:Sanofi collaboration revenue: 85.01M
Today's EPS Names:
TARO, BRLI, TLB, More
Regeneron Pharma (Nasdaq: REGN) shares are strongly higher Monday following its fourth-quarter report, but more importantly its outlook.
Regeneron said it now sees fiscal 2012 EYLEA sales in the US of $250 million to $300 million.
Otherwise, fourth-quarter adjusted loss came in at 27 cents per share, beating expectations calling for loss of 60 cents per share.
Shares are up about 12 percent early Monday morning.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Regeneron said it now sees fiscal 2012 EYLEA sales in the US of $250 million to $300 million.
Otherwise, fourth-quarter adjusted loss came in at 27 cents per share, beating expectations calling for loss of 60 cents per share.
Shares are up about 12 percent early Monday morning.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Savient Pharma (SVNT) Moves Higher with Volatility; Bumps Up Against Key Resistance Point
- F5 Networks (FFIV) Nears 200-Day DMA Support Level; Volatility Up on Early Dip
- Bill Gross Thinks China is the Real Elephant in the Room
Create E-mail Alert Related Categories
Guidance, Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
